Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02

Core Insights - Armata Pharmaceuticals is advancing its bacteriophage therapeutic AP-SA02 for complicated Staphylococcus aureus bacteremia, with topline data expected in Q2 2025 to support future pivotal trials [1][5] Funding and Support - The company has received an additional $4.65 million in non-dilutive funding from the Department of Defense, bringing the total award to $26.2 million to support the clinical development of AP-SA02 [1][2] Clinical Trial Details - The diSArm study is a Phase 1b/2a trial evaluating the safety, tolerability, and efficacy of intravenous AP-SA02 as an adjunct to best available antibiotic therapy for adults with complicated Staphylococcus aureus bacteremia [3][4] - The trial achieved full enrollment of 50 subjects by November 2024, with the last patient visit in January 2025, and demonstrated the ability to dose escalate to 5e10 PFU every six hours without significant adverse events [4][5] Manufacturing and Development Commitment - Armata is focused on demonstrating the potential of phage therapy through rigorously designed clinical trials and has developed a proprietary manufacturing process to support both clinical development and future commercial production [2][7]